BMEA vs. SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, ZYBT, CRDF, MREO, and KOD
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs. Its Competitors
Sagimet Biosciences (NASDAQ:SGMT) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.
Sagimet Biosciences' return on equity of -35.21% beat Biomea Fusion's return on equity.
In the previous week, Biomea Fusion had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Biomea Fusion and 1 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.33 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Sagimet Biosciences has higher revenue and earnings than Biomea Fusion. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Sagimet Biosciences has a beta of 3.35, indicating that its share price is 235% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.
87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 18.4% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Sagimet Biosciences presently has a consensus target price of $26.60, indicating a potential upside of 178.53%. Biomea Fusion has a consensus target price of $20.10, indicating a potential upside of 969.15%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Sagimet Biosciences.
Summary
Biomea Fusion beats Sagimet Biosciences on 8 of the 15 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 7/18/2025 by MarketBeat.com Staff